MedElevator
Войти в исследования International journal of cardiology · 2026
SGLT2 inhibitors and cardiovascular outcomes in patients with diabetes following hematopoietic stem cell transplantation: A propensity-matched cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yeo Yong Hao, Wong Hermon Kha Kin, Tan Jia Yi, Ong Tze Ern, Vignarajah Aravinthan, Koo Thai Hau, Vigneswaramoorthy Nishanthi, Donisan Teodora, Ayoub Chadi, Okwuosa Tochukwu M, Hayek Salim S
Аннотация
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) recipients are at increased risk of cardiovascular disease, and diabetes mellitus (DM) is common after transplantation. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardioprotective effects in diabetic populations, but their impact in HSCT recipients is unclear. We evaluated cardiovascular outcomes associated with SGLT2i use in diabetic HSCT patients.
METHODS: Using the TriNetX federated research network, we conducted a retrospective cohort study of patients with DM who underwent HSCT between 2014 and 2019. Patients were stratified by SGLT2i exposure. Outcomes were assessed from 100 days post-HSCT through 5 years. Primary endpoints included all-cause mortality, hospitalization, myocardial infarction, atrial fibrillation, and heart failure exacerbation. Propensity score matching (1:1) balanced baseline characteristics.
RESULTS: Among 11,682 diabetic HSCT patients, 1446 (12.4%) received SGLT2i. After matching (n = 1308 per group), SGLT2i use was associated with significantly lower all-cause mortality at 1 year (OR 0.54, 95% CI 0.41-0.71), 3 years (OR 0.56, 95% CI 0.45-0.69), and 5 years (OR 0.49, 95% CI 0.40-0.60; all p < 0.001). At 5 years, SGLT2i use was also associated with reduced hospitalization (OR 0.76, 95% CI 0.65-0.89; p < 0.001) and heart failure exacerbation (OR 0.80, 95% CI 0.68-0.95; p = 0.009). No significant differences were observed in myocardial infarction or atrial fibrillation. Findings were consistent across transplant types.
CONCLUSION: SGLT2i use was associated with reduced mortality, hospitalization, and heart failure events in diabetic HSCT recipients, with associations evident early and sustained through 5 years. Prospective studies are warranted.
METHODS: Using the TriNetX federated research network, we conducted a retrospective cohort study of patients with DM who underwent HSCT between 2014 and 2019. Patients were stratified by SGLT2i exposure. Outcomes were assessed from 100 days post-HSCT through 5 years. Primary endpoints included all-cause mortality, hospitalization, myocardial infarction, atrial fibrillation, and heart failure exacerbation. Propensity score matching (1:1) balanced baseline characteristics.
RESULTS: Among 11,682 diabetic HSCT patients, 1446 (12.4%) received SGLT2i. After matching (n = 1308 per group), SGLT2i use was associated with significantly lower all-cause mortality at 1 year (OR 0.54, 95% CI 0.41-0.71), 3 years (OR 0.56, 95% CI 0.45-0.69), and 5 years (OR 0.49, 95% CI 0.40-0.60; all p < 0.001). At 5 years, SGLT2i use was also associated with reduced hospitalization (OR 0.76, 95% CI 0.65-0.89; p < 0.001) and heart failure exacerbation (OR 0.80, 95% CI 0.68-0.95; p = 0.009). No significant differences were observed in myocardial infarction or atrial fibrillation. Findings were consistent across transplant types.
CONCLUSION: SGLT2i use was associated with reduced mortality, hospitalization, and heart failure events in diabetic HSCT recipients, with associations evident early and sustained through 5 years. Prospective studies are warranted.